Headquartered in Beverly, MA Fiscal year ends December NASDAQ: INGN provider.inogen.com
Inogen, Inc. (Nasdaq: INGN) is a global medical technology company that develops, manufactures, and markets innovative respiratory therapy products for homecare settings. The company's core products include portable oxygen concentrators (POCs) designed for patients suffering from chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen generates revenue through three channels: direct-to-consumer and business-to-business sales in the U.S., international sales through distributors, and a domestic rental program. The company is expanding its respiratory care portfolio beyond oxygen therapy, including the Simeox airway clearance device acquired through the Physio-Assist acquisition, and continues to launch new products such as the Rove 6 POC in international markets. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its devices widely available. Updated
Wednesday's top analyst upgrades and downgrades included Amazon.com, Beyond Meat, Compass, DraftKings, Genius Sports, Home Depot, International Flavors & Fragrances, Lowe's, Palantir Technologies, Telephone and Data Systems and Walmart.
Tuesday's top analyst upgrades and downgrades included Altria, American International Group, Datadog, DraftKings, Emerson Electric, Marriott International, NortonLifeLock, Opendoor Technologies, Realty Income, Roblox and Under Armour.
Thursday's top analyst upgrades and downgrades included Apple, DraftKings, Gap, Grubhub, Inogen, Kellogg, Lyft, ONEOK, Redfin, Uber Technologies, Yum Brands and Zillow.
Inogen, Inc. (Nasdaq: INGN) is a global medical technology company that develops, manufactures, and markets innovative respiratory therapy products for homecare settings.
The Wall Street consensus 12-month price target for INGN is $12.00.
